Zobrazeno 1 - 6
of 6
pro vyhledávání: '"PELF Regimen"'
Publikováno v:
Hospital Pharmacy. 47:834-840
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2eea283a20a6e5dbb9fa843e12ae0bd
https://doi.org/10.1310/hpj4711-834
https://doi.org/10.1310/hpj4711-834
Autor:
Giuseppe Comella, Anna Maria Baldelli, Vincenzo Catalano, Francesco Graziano, R Casaretti, Roberto Labianca, Stefano Cascinu, Sandro Barni, Luciano Frontini, Giuseppina Catalano
Publikováno v:
British Journal of Cancer
In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of cisplatin, epidoxorubicin, fluorouracil, leucovorin (PELF) plus filgrastim. Chemotherapy-na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a75b952632b9b196e27d4d1b04778d
https://doi.org/10.1054/bjoc.2000.1631
https://doi.org/10.1054/bjoc.2000.1631
Autor:
Riccardo Cellerino, Giuseppina Catalano, Francesco Graziano, M.A.A. Safi, R. Ficarelli, Stefano Cascinu
Publikováno v:
European Journal of Cancer. 33:1699-1702
This is a phase I study to determine the maximum tolerated dose (MTD) and toxicity of a combination of paclitaxel and 5-Fluorouracil (5-FU) in advanced gastric cancer patients. The patients, refractory to the PELF regimen (5-FU, leucovorin, cisplatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df87e89c77fa66bfcd6269176e06cb40
https://doi.org/10.1016/s0959-8049(97)00134-2
https://doi.org/10.1016/s0959-8049(97)00134-2
Autor:
Alain Gelibter, C. F. Pollera, Paolo Carlini, Alessandra Felici, Salvatore De Marco, Francesco Cognetti, Anna Maria Fariello, Isabella Sperduti, Enzo Maria Ruggeri, Teresa Gamucci, Ennio Adami, Luca Moscetti
Publikováno v:
Scopus-Elsevier
Background: It has been demonstrated that the 3-weekly PELF regimen is superior to FAM and FAMTX in advanced gastric cancer. The aim of this multicentric phase II study was to evaluate the efficacy and tolerability of a PELF regimen, given every 2 we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::384f8d81ae6ddca5b50f82c7d4274cbd
https://pubmed.ncbi.nlm.nih.gov/16001173
https://pubmed.ncbi.nlm.nih.gov/16001173
Autor:
D. Padalino, Fabrizio Nelli, M.G. Chilelli, Enzo Maria Ruggeri, T.V. Ranalli, V. Gomes, G. Natoli, Luca Moscetti, D. Giuliana, D. Arduini
Publikováno v:
Journal of Clinical Oncology. 28:e14603-e14603
e14603 Background: The role of the excision repair cross-complementing 1 (ERCC1) is well documented in a large number of tumor types with cisplatin-based chemotherapy. The aim of this study was to ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a603aec36f7ae608522e9994db15c85
https://doi.org/10.1200/jco.2010.28.15_suppl.e14603
https://doi.org/10.1200/jco.2010.28.15_suppl.e14603
Autor:
A. De Paoli, Diana Crivellari, S. Tumolo, Sergio Frustaci, Carlo Riccardo Rossi, S. Monfardini, Angela Buonadonna, Roberto Sigon, M. D. Magri
Publikováno v:
European Journal of Cancer. 32:S27
Reports on FAMTX (5-FU, high-dose methotrexate and doxorubicin), EAP (etoposide, doxorubicin, cisplatin) and PELF (cisplatin, epirubicin, leucovorin and 5-FU) showed that survival rates remain very poor (median 7.3 months for FAMTX, 6.1 for EAP and 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f07dc4df885bda20c35fd4cb2f2083d
https://doi.org/10.1016/0959-8049(96)84895-7
https://doi.org/10.1016/0959-8049(96)84895-7